EMEA-002398-PIP01-18
Key facts
| Active substance |
N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl) cyclobutyl)-3-phenylisoxazole-5-
|
| Therapeutic area |
Pneumology-allergology
|
| Decision number |
P/0191/2019
|
| PIP number |
EMEA-002398-PIP01-18
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of cystic fibrosis
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
SFL Pharmaceuticals Deutschland GmbH
Tel: +49 7621 5500 250 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|